BioSpace News Archive

Pharm Country

Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial

Updated results from a subgroup analysis of a first-in-human phase 1 trial showed that raludotatug deruxtecan continues to demonstrate promising clinical activity in patients with heavily pretreated platinum-resistant advanced ovarian cancer.

October 22, 2023
·
9 min read
BioForest

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

Astellas Pharma Inc. and Seagen Inc. announced results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy.

October 22, 2023
·
27 min read
Drug Development

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma Inc. presented updated data from its ongoing Phase 2 trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic Human Papillomavirus 16-positive head and neck cancer.

October 22, 2023
·
11 min read
Drug Development

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

Arvinas, Inc. announced the presentation of interim data from the Company’s Phase 1/2 clinical trial for bavdegalutamide, a novel PROTAC® protein degrader targeting the androgen receptor, in a poster session at the European Society for Medical Oncology Congress being held in Madrid from October 20 – 24, 2023.

October 22, 2023
·
11 min read
Drug Development

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Seagen Inc. and Genmab A/S announced results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy.

October 22, 2023
·
19 min read